Page 6,872«..1020..6,8716,8726,8736,874..6,8806,890..»

Parcell Laboratories Honored as 2012 SBANE Innovation Award Winner

Posted: Published on May 15th, 2012

NEWTON, Mass., May 14, 2012 /PRNewswire/ --Parcell Laboratories, a leading adult stem cell company based in Newton, MA, was awarded the prestigious 2012 Innovation Award by the Smaller Business Association of New England (SBANE). Parcell joins the select list of winning companies from the last 26 years whose innovations have delivered proven value to customers. SBANE uses its highly competitive Innovation Awards program to showcase technology driven enterprises that are potentially "game changers" in their markets. Parcell's ELA stem cell technology is a platform technology that has unlimited applications for tissue regeneration and is positioned to change the face of regenerative medicine. "We are honored to have been recognized by SBANE for our accomplishments and to be included among the roster of extremely successful companies that have been previous winners of the award," said Pamela Layton, the CEO of Parcell Laboratories. "The award is a testament to the dedication and tenacity of our terrific team." Past award winners include some of the most recognizable names in New England business, including Staples, Genzyme, Ben & Jerry's and Nantucket Nectars. Parcell Laboratories holds the license and intellectual property to the ELA stem cell, which is considered to be the earliest lineage adult … Continue reading →

Posted in Cell Medicine | Comments Off on Parcell Laboratories Honored as 2012 SBANE Innovation Award Winner

VistaGen CEO Issues Update Letter to Stockholders

Posted: Published on May 15th, 2012

SOUTH SAN FRANCISCO, CA--(Marketwire -05/14/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA) (VSTA.OB), a biotechnology company applying stem cell technology for drug rescue, today issued the following letter to its stockholders and the investment community from its CEO, Shawn Singh. To our valued Stockholders: Since becoming a public company one year ago, we have progressed to perhaps the most exciting time in our company's 14-year history. To arrive at this point, more than $45 million, obtained through various strategic collaborations, investments and grant awards, has been carefully employed. We believe our pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, combined with the network of strategic relationships we have announced, will allow us to secure additional capital and the large market drug rescue opportunities that can deliver value to our stockholders. Since the beginning of the year, our team has carefully reviewed our Top 10 drug rescue opportunities and narrowed our focus to our Top 5 candidates. Now we intend to launch our initial drug rescue program and secure strategic capital necessary to support it, as well as launch our second drug rescue program by year-end. We also are working on validation of LiverSafe 3D, our bioassay system for … Continue reading →

Posted in Cell Medicine | Comments Off on VistaGen CEO Issues Update Letter to Stockholders

Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives

Posted: Published on May 15th, 2012

DENVER, May 14, 2012 /PRNewswire/ -- Regenerative Sciences, Inc., a company dedicated to advancing orthopedic care through non-surgical adult stem cell procedures, today announced that it has secured a $2M investment from philanthropist, visionary and businessman John C. Malone, PhD, chairman of Liberty Media Corporation. In addition to advancing Regenerative Sciences' clinical and lab-based stem cell research, the investment will help support the national expansion of their Regenexx Physician Network. Regenerative Sciences' Regenexx procedures utilize a patient's own stem cells to help repair a broad range of common injuries and degenerative conditions, including cartilage lesions, torn ligaments and tendons, osteoarthritis and bulging spinal discs. For many, the procedures offer a viable alternative to arthroscopic surgery, open-joint surgery, or joint replacement surgery. Regenexx patients experience little or no downtime from the procedures and avoid the lengthy rehabilitation period associated with most surgical procedures. "We are proud of our accomplishments in the field of regenerative interventional orthopedics and it's exciting that our work has drawn the attention of such a noted entrepreneur and philanthropist," said Christopher J. Centeno, M.D., Chief Executive Officer of Regenerative Sciences. "Dr. Malone shares our vision for forging the next generation of minimally invasive regenerative treatments. This investment … Continue reading →

Posted in Cell Medicine | Comments Off on Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives

Research and Markets: Stem Cell Research Products: Opportunities, Tools & Technologies 2012 (Updated)

Posted: Published on May 15th, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/lffnp7/stem_cell_research) has announced the addition of the "Stem Cell Research Products: Opportunities, Tools & Technologies 2012 (Updated)" report to their offering. Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Several broad categories of stem cells exist, including embryonic stem cells, derived from blastocysts; fetal stem cells, obtained from aborted fetuses; adult stem cells, found in adult tissues; cord blood stem cells, isolated from umbilical tissue; dental stem cells, derived from deciduous teeth; cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body; and animal stem cells, derived from non-human sources. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem and progenitor cells act as a repair system for the body, replenishing specialized cells. Of interest to researchers is the potential for use of stem cells in regenerative medicine to treat conditions ranging from diabetes, to cardiovascular disease and neurological disorders. Additionally, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest … Continue reading →

Posted in Cell Medicine | Comments Off on Research and Markets: Stem Cell Research Products: Opportunities, Tools & Technologies 2012 (Updated)

Research and Markets: Stem Cell Research Products: Opportunities, Tools & Technologies 2012 (Updated)

Posted: Published on May 15th, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/lffnp7/stem_cell_research) has announced the addition of the "Stem Cell Research Products: Opportunities, Tools & Technologies 2012 (Updated)" report to their offering. Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Several broad categories of stem cells exist, including embryonic stem cells, derived from blastocysts; fetal stem cells, obtained from aborted fetuses; adult stem cells, found in adult tissues; cord blood stem cells, isolated from umbilical tissue; dental stem cells, derived from deciduous teeth; cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body; and animal stem cells, derived from non-human sources. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem and progenitor cells act as a repair system for the body, replenishing specialized cells. Of interest to researchers is the potential for use of stem cells in regenerative medicine to treat conditions ranging from diabetes, to cardiovascular disease and neurological disorders. Additionally, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest … Continue reading →

Posted in Cell Medicine | Comments Off on Research and Markets: Stem Cell Research Products: Opportunities, Tools & Technologies 2012 (Updated)

Senesco to Present SNS01-T, an eIF5A-based Nanoparticle in a Phase 1b/2a Trial to Treat Multiple Myeloma, is Effective …

Posted: Published on May 15th, 2012

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Senesco Technologies, Inc. (Senesco or the Company) (NYSE Amex: SNT), announced today that an oral presentation will be delivered at the 15th Annual Meeting of the American Society of Gene & Cell Therapy. The conference will be held May 16-19th, 2012 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. The Company will present during the Cancer-Targeted Gene & Cell Therapy Oral Abstract Session, which will begin Thursday, May 17, at 1:15 P.M. Eastern Time. The oral presentation, entitled SNS01-T, an eIF5A-Based Gene Therapy Nanoparticle Designed for the Treatment of Multiple Myeloma, has Anti-Tumoral Activity in Lymphoma, will describe the effectiveness of SNS01-T in B-cell cancers, which is designed to selectively induce programmed cell death. The talk will be delivered by Catherine Taylor who is from Senesco CSO John Thompsons research laboratory at the University of Waterloo in Ontario, Canada. About Multiple Myeloma Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies, in which abnormal cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal blood cells. Senesco was previously granted orphan drug status for … Continue reading →

Posted in Cell Therapy | Comments Off on Senesco to Present SNS01-T, an eIF5A-based Nanoparticle in a Phase 1b/2a Trial to Treat Multiple Myeloma, is Effective …

Hanover pharmacist suspended over excessive narcotics prescriptions

Posted: Published on May 15th, 2012

N.H. Board of Pharmacy has temporarily suspended the state pharmacy license of Jeffrey A. Licht after an investigation found Licht was being prescribed excessive amounts of a narcotic. Licht, a registered pharmacist, worked in Pharmacy Services at Dartmouth College Health Services, according to a staff listing on the colleges website. A Dartmouth spokesman did not respond by deadline. A professional misconduct hearing is set for 10 a.m. Wednesday at the Board of Pharmacy office at 57 Regional Drive, Concord. In an order dated May 11, the Board of Pharmacy said an investigation showed Licht diverted hydrocodone/acetaminophen from Dicks House, which is part of Dartmouth College Health Services. Hydrocodone is an opiate. Reached by phone in Hanover, Licht called the charges ludicrous. I think they will be dropped out of hand, Licht said. He said he had no attorney and would represent himself at the hearing Wednesday. Im just sorry that people become guilty before there is even a hearing. I dont have anything to say about the case except that nothing in it is true, he said. The Pharmacy Boards complaint said Licht was prescribed 9,761 tablets of hydrocodone/acetaminophen between August 2010 and March 2012 from a physician who was … Continue reading →

Posted in Prescriptions | Comments Off on Hanover pharmacist suspended over excessive narcotics prescriptions

Effects Of ADHD – Video

Posted: Published on May 15th, 2012

14-05-2012 03:54 The effects of ADHD on a person's life, career and relationships can be disastrous especially if it is diagnosed very late. This is quite common because very often ADHD goes undiagnosed. Then there is the whole question about the effects of ADHD meds such as Ritain on a person's life as they can be very disturbing and upsetting. They are very much a two-edged sword as they can help to relieve the symptoms of restlessness and help the person or child to focus and that is really a blessing in many cases. But there are many side effects as well and that can also be problematic. But apart form the meds, the effects of ADHD are very far reaching because they prevent a person from performing according to the norms and demands of our modern society. We insist on deadlines on results and on focus. The child will more likely have problems at school and at college and that is why it is so important to teach them life coping skills and behaviour therapy to deal with behavior problems and social issues. This is the best way of lessening the effects of ADHD http See the rest here: … Continue reading →

Posted in Drug Side Effects | Comments Off on Effects Of ADHD – Video

FDA Panel Recommends Approval of Another Iffy Weight-Loss Drug

Posted: Published on May 15th, 2012

Pharmaceutical companies are rushing to produce new weight loss drugs. But some of them come along with alarming side effects. FBellon/Flickr I was riveted by an article in today's New York Times about the latest decision of an FDA drug advisory panel. The panel voted to approve a new weight-loss drug, lorcaserin. The vote was mixed: 18 for approval, four against, and one abstention. The majority felt that the benefits outweighed the risks and that even if there were risks, "new tools are needed to treat a major health problem." The benefits are worth a look. What about the risks? The drug: Also in the Times is a piece by Dr. Danielle Ofri on her experience with patients who want weight-loss drugs. She quotes from an essay called "Lemons for Obesity" by Dr. Michael S. Lauer, who was a minority voter on the FDA panel that approved the weight-loss drug Qnexa earlier this year. The weight-loss field is strewn with lemons, more so than other areas of medicine, Dr. Lauer argues. Because of the enormous potential market for these drugs -- two-thirds of American adults are overweight or obese -- pharmaceutical companies rush new drugs to market after conducting only … Continue reading →

Posted in Drug Side Effects | Comments Off on FDA Panel Recommends Approval of Another Iffy Weight-Loss Drug

Anti-Obesity Drugs a Hot Topic in the Biotech Industry

Posted: Published on May 15th, 2012

NEW YORK, NY--(Marketwire -05/14/12)- Biotech companies are looking to cash in on the anti-obesity drug market. The race to bring the first weight-loss pill to the market is heating up as Arena Pharmaceuticals weight-loss pill (Lorcaserin) recently gained the backing of an FDA advisory panel. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on VIVUS, Inc. (VVUS) and Roche Holding Ltd. (RHHBY.PK). Access to the full company reports can be found at: http://www.ParagonReport.com/VVUS http://www.ParagonReport.com/RHHBY Arena is currently competing with Vivus and Orexigen Therapeutics to bring the first anti-obesity drug to the market in nearly 13 years. All three of the companies' drugs were previously turned down by the FDA. FDA advisers last week voted 18-4 that the benefits of Arena's Lorcaserin outweigh the health risks. According to recent numbers from the Center for Disease Control and Prevention over 78 million adults in the U.S. are obese. Obesity significantly raises the risks for health problems such as diabetes, heart attacks, and strokes. It is estimated that obesity costs the U.S. economy $147 billion a year in medicals costs and lost productivity. Paragon Report releases regular market updates on the Biotech Industry so investors can stay … Continue reading →

Posted in Drugs | Comments Off on Anti-Obesity Drugs a Hot Topic in the Biotech Industry

Page 6,872«..1020..6,8716,8726,8736,874..6,8806,890..»